Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

How will Brexit effect Multinationals and Pharmaceutical Companies?

Posted on June 30th, 2016 by in Pharma R&D

One of the most stunning upsets to happen in global politics in decades transpired on June 23 when the people of the United Kingdom voted to leave the European Union. Continue reading “How will Brexit effect Multinationals and Pharmaceutical Companies?” »

The Fundamentals of Good Data Stewardship

Posted on June 29th, 2016 by in Pharma R&D

Bioactivity data is not in short supply. The days of limited availability of data on compounds and biological targets are long behind us. Continue reading “The Fundamentals of Good Data Stewardship” »

What Does the 2016 US Election Mean For Pharma?

Posted on June 28th, 2016 by in Pharma R&D

With summer, the 2016 U.S. Presidential Election is now truly heating up as we have presumptive nominees from the two major political parties. While we are hearing a lot about issues like national security and immigration from Republican nominee Donald Trump and Democratic nominee Hillary Clinton, those working in the pharmaceutical industry may be wondering how their sector will be affected by the eventual winner. Continue reading “What Does the 2016 US Election Mean For Pharma?” »

The Changing Competencies of Pharmacovigilance Leadership

Posted on June 27th, 2016 by in Pharmacovigilance

Significant transformations happened over the last decade regarding the role of pharmacovigilance (PV) departments in pharmaceutical organizations. This had a tremendous impact not only on the technical knowledge needed, but more importantly on the non-technical competencies that should be required for any PV role in pharma. Continue reading “The Changing Competencies of Pharmacovigilance Leadership” »

  1. 1
  2. 2
  3. 3
  4. 4